Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Discovery of BLU-667 for RET driven cancers
Jason Brubaker
Blueprint Medicines, Cambridge, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Discovery and development of USP7 inhibitors
Tim Harrison
Almac Discovery, Belfast, Ireland
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Identification and optimization of chemical series that lead to discovery of erdafitinib: A potent pan-fibroblast growth factor receptor (FGFR) inhibitor
Patrick Angibaud
Janssen R & D, Val-de-Reuil, France
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680
Jenna Jeffrey
Arcus Biosciences, Inc., Hayward, CA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4